Humacyte, Inc. disclosed preliminary financial information for the year ended December 31, 2025, estimating $50.9 million in cash, cash equivalents and restricted cash, $2.0 million in total revenue including $1.4 million in product revenue, and 61 unit sales of Symvess. The company suspended and terminated its ATM prospectus for up to $60 million of common stock and provided commercial and regulatory updates including a $1.48 million purchase commitment in KSA and an MAA filing in Israel.
Key takeaways
Preliminary cash, cash equivalents and restricted cash of $50.9 million as of December 31, 2025.
Preliminary total revenue of $2.0 million, including $1.4 million product revenue, for year ended December 31, 2025.
61 unit sales of Symvess for year ended December 31, 2025.
Suspended and terminated ATM Prospectus for $60 million common stock sales effective March 19, 2026.
Received $1.48 million minimum purchase commitment for Symvess in KSA on March 4, 2026.
Filed MAA for Symvess vascular trauma indication with Israel Ministry of Health on March 16, 2026.